Growth Metrics

Travere Therapeutics (TVTX) Long-Term Debt Issuances (2022)

Travere Therapeutics (TVTX) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $316.2 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Long-Term Debt Issuances changed N/A year-over-year to $316.2 million, compared with a TTM value of $316.2 million through Dec 2022, changed N/A, and an annual FY2022 reading of $316.2 million, changed N/A over the prior year.
  • Long-Term Debt Issuances was $316.2 million for Q1 2022 at Travere Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $316.2 million in Q1 2022 and bottomed at $316.2 million in Q1 2022.